article · Gastrointestinal Disorders
The human microbiome regulates critical physiological processes, including digestion, immunity, and metabolic functions. Modulating these complex microbial communities offers significant potential for treating diverse conditions, ranging from inflammatory bowel disease and metabolic disorders to neurological diseases and cancer. Key therapeutic strategies currently being developed and assessed include probiotics, prebiotics, faecal microbiota transplantation, and targeted microbial-based drugs. Alongside these interventions, the integration of microbiome profiling with metagenomic data is helping to advance precision medicine by enabling personalised treatment approaches. However, several clinical implementation challenges remain before these therapies can be widely deployed. Synthesising recent developments, current research identifies critical knowledge gaps while setting out the evolving pathways through which microbiome science could deliver targeted, individualised healthcare solutions.
Understanding the link between gut microbes and chronic illnesses is transforming modern healthcare approaches. By shifting from standard generalised treatments to therapies that target or utilise specific microbial ecosystems, medical interventions can become more precise and effective. This approach holds promise for managing severe disorders, improving long-term health outcomes, and creating personalised medical solutions tailored to an individual's unique biological profile.
The work points towards commercial applications in personalised healthcare, specifically the development of microbiome profiling tools, diagnostics, and therapeutics such as prebiotics, probiotics, faecal transplants, and microbial drugs. These would serve clinicians, diagnostic laboratories, and pharmaceutical companies treating conditions like cancer, metabolic disorders, and inflammatory bowel disease. However, as a review discussing implementation challenges, the field spans early-stage drug development to clinical integration, with significant barriers remaining before broad market adoption.
AI-generated from the published abstract. Always read the original work before citing.
The human microbiome, a complex ecosystem of microorganisms residing in and on the body, plays a pivotal role in the regulation of a wide range of physiological processes, including digestion, immune responses, and metabolic functions. In recent years, the rapidly growing field of microbiome-driven therapeutics has garnered significant attention owing to its potential to revolutionize healthcare. This review explores the evolving landscape of microbiome-based therapies, with a particular focus on the gut microbiome and its implications for both gut health and precision medicine. We highlight recent advances in understanding how microbial communities influence disease pathogenesis and treatment outcomes, spanning conditions such as inflammatory bowel disease (IBD), metabolic disorders, neurological diseases, and even cancer. This article also discusses emerging therapeutic strategies, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and microbial-based drugs, as well as the challenges associated with their clinical implementation. Additionally, we examined how the integration of microbiome profiling and metagenomic data is advancing the field of precision medicine, paving the way for personalized and effective treatments. This review serves as a comprehensive resource that synthesizes current knowledge, identifies key gaps in microbiome research, and offers insights into the future direction of microbiome-driven therapeutics, thus providing a valuable framework for clinicians, researchers, and policymakers seeking to harness the potential of microbiomes to advance personalized healthcare solutions.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/gidisord7010007
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
